Literature DB >> 28918474

Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium.

Daniel Hao Lin1, Arijit Biswas1, Mahesh Choolani1, Chui-Yee Fong1, Ariff Bongso2.   

Abstract

Strategies that induce immunogenic cell death (ICD) or downregulate CD47 or PD-L1 expression have resulted in successful therapeutic options for tumor eradication. Several groups have reported the tumoricidal effects of human umbilical cord Wharton's jelly stem cells (hWJSCs) or its conditioned medium (hWJSC-CM) on certain cancers but the mechanisms have not been elucidated. Since hWJSCs possess immunomodulatory properties, we investigated whether one of the tumoricidal mechanisms was via ICD. We first concentrated hWJSC-CM into a 3 kDa concentrate and then exposed various concentrations of this concentrate to human lymphoma cells to find out which concentration had the greatest tumoricidal effect. We observed that a 500 µg/ml concentration of the concentrate had the greatest inhibitory effect. Thereafter, lymphoma cells were exposed to 500 µg/ml of the hWJSC-CM-3 kDa concentrate and then subjected to analysis for morphology, viability, apoptosis, mitochondrial and endoplasmic reticulum stress, danger associated molecular patterns (DAMP), extracellular HMGB1, CD47 and PD-L1 markers and dendritic cell phenotype. Extensive nuclear chromatin and mitochondrial changes with significantly decreased cell viability and increased apoptosis were observed in the treated lymphoma cells compared to controls. There were also significant increases in the release of DAMPs, extracellular HMGB1 and dendritic cell activation and maturation, with concomitant decreases in CD47 and PD-L1 expression in the treated cells compared to controls. In other ongoing studies we observed increased expression of specific tumor-suppressor molecules (miRNA-146a and miRNA-126, MCP-1, IL-6, IL-8 and IL-12) in hWJSC-CM suggesting that one or more of these molecules may be the modulators of the ICD.

Entities:  

Keywords:  3 kDa molecular weight concentrate; Cancer cell inhibition; Danger-associated molecular patterns; Human wharton jelly stem cell conditioned medium; Immunogenic cell death; Lymphoma

Mesh:

Substances:

Year:  2017        PMID: 28918474     DOI: 10.1007/s12015-017-9767-8

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  81 in total

Review 1.  Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives.

Authors:  Jérémie Dalous; Jérome Larghero; Olivier Baud
Journal:  Pediatr Res       Date:  2012-02-08       Impact factor: 3.756

2.  A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys.

Authors:  Youwei Wang; Zhi-Bo Han; Jinling Ma; Conglin Zuo; Jie Geng; Wei Gong; Yunxia Sun; Hongzhen Li; Bin Wang; Lei Zhang; Yanan He; Zhong Chao Han
Journal:  Stem Cells Dev       Date:  2011-11-22       Impact factor: 3.272

3.  The extracellular release of HMGB1 during apoptotic cell death.

Authors:  Charles W Bell; Weiwen Jiang; Charles F Reich; David S Pisetsky
Journal:  Am J Physiol Cell Physiol       Date:  2006-07-19       Impact factor: 4.249

4.  Human umbilical cord Wharton's jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo.

Authors:  C Y Fong; K Gauthaman; S Cheyyatraivendran; H D Lin; A Biswas; A Bongso
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

Review 5.  Intraplacental choriocarcinoma in a term placenta with both maternal and infantile metastases: a case report and review of the literature.

Authors:  Jianping Liu; Lina Guo
Journal:  Gynecol Oncol       Date:  2006-09-26       Impact factor: 5.482

6.  Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease.

Authors:  Mark L Weiss; Satish Medicetty; Amber R Bledsoe; Raja Shekar Rachakatla; Michael Choi; Shosh Merchav; Yongquan Luo; Mahendra S Rao; Gopalrao Velagaleti; Deryl Troyer
Journal:  Stem Cells       Date:  2005-10-13       Impact factor: 6.277

Review 7.  Doxorubicin cardiomyopathy.

Authors:  Kanu Chatterjee; Jianqing Zhang; Norman Honbo; Joel S Karliner
Journal:  Cardiology       Date:  2009-12-11       Impact factor: 1.869

8.  Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.

Authors:  A Q Sukkurwala; I Martins; Y Wang; F Schlemmer; C Ruckenstuhl; M Durchschlag; M Michaud; L Senovilla; A Sistigu; Y Ma; E Vacchelli; E Sulpice; X Gidrol; L Zitvogel; F Madeo; L Galluzzi; O Kepp; G Kroemer
Journal:  Cell Death Differ       Date:  2013-06-21       Impact factor: 15.828

9.  ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages.

Authors:  Gizem Ayna; Dmitri V Krysko; Agnieszka Kaczmarek; Goran Petrovski; Peter Vandenabeele; László Fésüs
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

10.  Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo.

Authors:  Shuai Wu; Guan-Qun Ju; Tao Du; Ying-Jian Zhu; Guo-Hua Liu
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more
  2 in total

Review 1.  Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications.

Authors:  Wei-Zhan Zhuang; Yi-Heng Lin; Long-Jyun Su; Meng-Shiue Wu; Han-Yin Jeng; Huan-Cheng Chang; Yen-Hua Huang; Thai-Yen Ling
Journal:  J Biomed Sci       Date:  2021-04-14       Impact factor: 8.410

Review 2.  Stem Cell as Vehicles of Antibody in Treatment of Lymphoma: a Novel and Potential Targeted Therapy.

Authors:  Jiayi Zhang; Zhaohu Yuan; Weijie Zhong; Yaming Wei
Journal:  Stem Cell Rev Rep       Date:  2020-11-17       Impact factor: 5.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.